

Index

- acalculia 388
- adaptive rejection sampling 88
- adjusted likelihood estimator 265
- affected sib pair (ASP) 346, 348
 - lod score 354–5
 - parametric modelling 347
- aggregated information 307
- agraphia 388
- AIDS 138
- Akaike's information criterion (AIC) 52, 102, 174–5
- all-cause mortality curve 228
- allele frequencies 340
- alleles 328–9, 332, 340, 342, 345
- American Board of Internal Medicine (ABIM), Patient Satisfaction Questionnaire 49
- American Thoracic Society (ATS) 7
- analysis of covariance (ANCOVA) 10, 15–16
 - with random effects 56–9
- analysis of variance (ANOVA) 254, 372, 377
- angosia 388
- approximate likelihood 290–1, 314
- AR(1) structures 148, 166, 170, 197–8
- AR(1)+RE 166–7, 179
- AR(1)@UN 206
- at-risk population 427
- autocorrelation function (ACF) 90
- autoregressive correlation structure 31
- autoregressive with random effect for patient 170–1
- autosomal chromosomes 340
- autosomal loci 328
- autosomal trait 328
- autosomes 328

- bandwidth limited function 396
- base pairs 340
- Bayesian analysis 234
- Bayesian approach 209–10, 216, 264, 434–5
- Bayesian Inference Using Gibbs Sampling *see* BUGS
- Bayesian information criterion (BIC) 53, 102
- Bayesian models 88–91, 432–5
 - advanced 435–6
 - empirical 321
 - hierarchical 321
- Bayesian residual 438
- Bayesian statistics in meta-analysis 321–2
- BCG vaccine against tuberculosis 293
- BEAM 436

- best linear unbiased estimates (BLUE) 160, 184
- best linear unbiased prediction (BLUP) 44, 59, 138
- beta-binomial likelihood 239–43
- beta-binomial model 228
- binomial likelihood 237
- bivariate approach 299–307
- bivariate data, more precise analysis 314
- bivariate meta-analysis with covariates 311–14
- bivariate random effects model 301–6, 315
- bivariate regression model 311
- block diagonal structure 72
- blocking factor 87
- blood types 329
- BMDP 145, 154–6
- BMDP 5V 144, 160, 188
- BMI 95–126
 - analysis of 96
- BMI growth curves
 - based on cross-sectional analysis 121
 - clinical implication of development 103–4
 - databases 104–6
 - discussion of results 117–22
 - model construction 106–8
 - models considered 109–13
 - pooled data 106
 - practical implication 121
 - results 113
 - smoking data 117
 - statistical analyses 106–13
- BMI prediction over time 115
- body mass index *see* BMI
- Bonferroni correction 404
- bootstrapping 91–2, 441
- brain, in action 398
- brain damage 385–7
- brain function 385
 - localization 385
- brain structure 386
- brain tissue 391
- Brief Psychiatric Rating Scale (BPRS) 131, 142–4, 146–7
- Broca's area 385
- Brodmann's areas 385
- BUGS 264, 268, 272–3, 279, 321, 436
 - output for random-effects lidocaine meta-analysis 285–6
- bump function 222–3
- BYM model 439–41

- cardiovascular death
 - distribution by clinic 243
 - distribution of probability 244
 - probability 227, 231
 - relative risk 232–3
 - relative risk of estimated baseline risk 231
 - cardiovascular risk factors 230
 - distribution of baseline 244
 - carriers 329
 - case events, mapping 427
 - CD4 count 138
 - Centers for Disease Control and Prevention (CDC) 104
 - cerebrospinal fluid 391
 - chi-square distribution 345
 - chi-statistic 13
 - childhood, leukaemia and lymphoma 427
 - children
 - pulmonary function development 133
 - model selection and checking 149–54
 - cholesterol in CHD risk estimation 449
 - chromosomes 328, 340
 - class discovery 364
 - class prediction 373–6
 - classification error 374
 - classification rules 374
 - cluster analysis 364–5
 - clustered data 3–33, 129
 - COMP model 206–8
 - complementary DNA (cDNA) 362–3, 378
 - complex traits, genetic mapping 339–59
 - composite covariance models 199–200
 - composite hypotheses 216–17
 - transforming into simple ones 234
 - compound symmetric (CS) covariance structure 169–70
 - compound symmetric (CS) structure 166, 178, 198
 - compound symmetry 197
 - conditional distributions 89
 - conditional likelihood for relative risk 235–9
 - conditional predictive ordinates (CPOs) 438
 - confidence interval 216, 291–2, 296–9
 - continuous risk factors 463
 - contrast-to-noise ratio 401
 - convolution, Fourier transform in 396–7
 - coronary heart disease (CHD)
 - multivariable models 447–76
 - risk estimates 447
 - risk factors 447–8
 - spatial distribution 428
 - correlated data
 - regression analysis 127
 - use of term 129
 - correlated heterogeneity 433
 - correlated responses 3–33
 - correlation, Fourier transform in 396–7
 - correlation coefficients
 - unstructured 32
 - user fixed 32
 - correlation matrix 140
 - correlogram 173
 - cosegregation 341
 - covariance, Fourier transform in 396–7
 - covariance components
 - estimating techniques 43–4
 - HLM/2L 53–5
 - hypothesis tests 45
 - SAS Proc Mixed 53–5
 - covariance matrix 312–13
 - sampling distribution 184
 - 3 x 3 89
 - covariance models 197–206
 - for nested repeated measures data 187–208
 - covariance parameters 197
 - covariance structure 72
 - comparison of fits 173–5
 - effects on tests of fixed effects, estimates of fixed effects and standard errors of estimates 175–80
 - example data set 160–2
 - for repeated measures 165–7
 - modelling 159–85
 - repeated measures data analysis 183
 - Cox proportional hazards model 464–74
 - Cox proportional hazards regression models 449
 - Cox regression models 133
 - Cronbach's alpha internal consistency reliability coefficient 49
 - cross-classification 82–3
 - cross-covariance function 397
 - cross-over design 134
 - cross-validation 374
 - crude Bayesian residual surface 441
-
- data resolution 4, 8, 12–13, 28
 - Data Safety Monitoring Committee (DSMC) 233–4
 - delta method 301
 - dendrogram from average linkage hierarchical clustering 366
 - diagnosis of adult-onset diabetes 225
 - diagnostic test for disease 212–13, 218
 - diallelic loci 329, 343, 351
 - dichotomous traits 329
 - difference measures, more precise analysis 316
 - diffuse prior distributions 89
 - Diggle model 141, 149, 151
 - discrete Fourier transform 397

- discrete genotypes 332–3
- discrete phenotypes 332–3
- disease cases, count of 424
- disease clustering 424
- disease counts within tracts 426, 428–9, 431–2
- disease distribution, crude representation 426
- disease incidence, status of area 427
- disease incidence data, representation 425
- disease mapping
 - applications 423
 - basic models 430–2
 - basic situations 424
 - case-event data 430–1
 - case study 439–42
 - discussion 442
 - exploratory methods 430
 - likelihood models 430
 - overview 423–4
 - reconstruction 423–44
 - restoration 425–36
 - statistical methods and issues 424
- DNA 328
 - overview 362
- DNA sequence 329, 361
- dominant trait 329
- dose-response curve data 128
- double heterozygote 332
- doubly repeated measures 188
- dummy variables 461

- echo-planar imaging (EPI) 392, 397–8
- ecological analysis 424
- effect size 259
- effective population size 344
- Elston–Stewart (peeling) algorithm 342
- EM algorithm 301
- empirical Bayes estimates 44, 138, 141, 151, 154, 315
- empirical Bayes methods 116, 129, 434–6, 442
- empirical Bayes model 321
- empirical Bayes relative risk estimates 435
- empirical power spectrum 398
- empirical spectral density 398
- ERIC (Educational Resources Information Center) 254
- estimated standard error 45
- estimating techniques
 - covariance components 43–4
 - fixed effects 43
 - hierarchical linear modelling 42–4
 - random effects 44
- estimation
 - HLM/2L 39–45
 - SAS Proc Mixed 39–45
- Euler characteristic 406
- evidential paradigm 210–17, 219

- F* tests 176
- F*-statistics 368
- familial distributions of medical traits 327
- family studies 327
- fast Fourier transform algorithm 397
- FEVU1u 133–4, 138, 142, 149–52, 154, 161–3, 165, 172, 180, 184
- Fieller’s method 301
- Fisher’s linear discriminant function 373–6
- fixed coefficients 100
- fixed effects 10, 159
 - design matrix 137
 - estimates of 183
 - estimating techniques 43
 - HLM/2L 53–5
 - hypothesis tests 45
 - SAS Proc Mixed 53–5
- fixed effects model 253, 260–1, 263, 265–6, 293–6
- fixed parameter estimates 304
- fixed parameters 71
- fMRI 383–422
 - aim of 387
 - basic principals 388–402
 - binary mask 413
 - case study 411–17
 - complots 414
 - computing summary images 414
 - design of experiments 418
 - discussion 417–19
 - echo-planar imaging (EPI) 392, 397–8
 - effective spatial resolution 400, 414–15
 - example 388
 - field gradients 393
 - gradient history space 393
 - homogeneous stochastic processes 407
 - image collection and data structures 411–12
 - image pre-processing 412–14
 - image quality 398–402
 - image quality measures 400
 - k*-space 393
 - low-variance screen 413–14
 - magnetic fields 392
 - non-parametric methods 404–5
 - orthogonal gradient fields 392
 - outline of tutorial 384
 - parametric methods 405–11
 - phase-encode direction 395
 - practical measures of image quality 401–2
 - primary imaging parameters 399–400
 - results of case study 415–17
 - results of experiments 418
 - signal generation 389–93
 - significance by spatial extent 410–11
 - spatial and temporal smoothness 407–8
 - spatial resolution 398
 - spatial time series analysis 402–11

- 3D localization and measurement 389–93
 - trade-offs 401
 - two-dimensional 395
 - see also* human brain mapping
- founders/non-founders 330
- Fourier coefficients 394
- Fourier frequencies 394
- Fourier methods for image reconstruction 393–7
- Framingham Heart Study (FHS) 104, 447–76
- frequentist approach 209–10, 434
- full Bayes methods 436
- full Bayesian model (BYM) 440
- full information maximum likelihood estimation (FIML) 100
- functional equation approach 306
- functional magnetic resonance imaging *see* fMRI
- funnel plots 267

- gametes 328, 341
- Gaussian autocovariance function 408
- Gaussian density 399
- Gaussian distribution 399
- Gaussian random fields 405–6
- gene expression, overview 361–3
- gene expression data analysis 361–79
 - discussion 376–8
 - example 364–76
 - statistical questions 363–4
- gene identification 370–2
- genealogy, specification 331
- general heterogeneity 433
- general linear mixed model (GLMM) 127–58, 184, 314, 320
 - case studies 130–3, 144–54
 - design considerations 134–5
 - development 134–43
 - equation defining 137
 - estimation and testing 137–8
 - extension 141
 - missing data 142–3
 - model checking 141–2
 - model development 135–7
 - model selection 138–41
 - modelling the mean 138–40
 - modelling the variance 140–1
- generalized estimating equations (GEEs) 3–33, 120, 206
 - correlation structures 31–2
 - models 9, 13, 71
 - with exchangeable correlation structure 16–17
- generalized least squares (GLS) 43, 177
 - estimator 137
 - fixed effects estimates 160
 - theory 184
- generalized linear models 8, 85–6
 - generic prior distributions 89
 - genes 328, 340, 362
 - genetic background 330
 - genetic data set 353
 - analysis 354
 - genetic drift 344
 - genetic epidemiology 327–38
 - aim of 327–8
 - sampling design and strategy in 335–6
 - genetic mapping of complex traits 339–59
 - example 352–5
 - genetic marker 341
 - genetic models 340
 - components of 330, 340
 - specification 330–3
 - terminology 328–30
 - genetic terminology 327, 340–4
 - genetic traits, distribution of 336
 - genotypes 328, 330–4, 340, 344–6
 - Gibbs–Metropolis samplers 436
 - Gibbs sampling 88–9, 436
 - goodness-of-fit (GOF) 108–9, 310, 437–9
 - gradient pulses 392
 - Gram–Schmidt orthonormalization 406–7
 - grey matter 383–4, 391
 - growth curve data 128
 - growth curves
 - development of 95–126
 - graphical representation 98
 - model fitting 101
 - see also* BMI growth curves
 - growth function, individual and group 99

 - haemodynamic response functions 408–9
 - haplotype 340, 351
 - haplotype frequencies 343
 - Haseman–Elston regression model 349
 - hazard function 87
 - hazard rates versus relative risk 229
 - Hedges' g 259
 - Henry A. Murray Research Center 104
 - heterogeneity
 - between studies 307
 - global measure of 433
 - heterogeneity tests 292, 346
 - heterozygotes 329
 - heterozygous genotype 340
 - hierarchical clustering 365
 - hierarchical data modelling 69
 - hierarchical data structures 35–6
 - three-level 36
 - two-level 36–7
 - hierarchical linear modelling 35–68, 95–126
 - analysis of simulated data 60
 - applications concerning continuous dependent variables 38
 - assumptions 39

- combined model 38–9
- estimation techniques 42–4
- HLM/2L 40–1, 61–2
- hypothesis testing 44–5
- level 1 37–9
- level 2 37–9
- meta-analysis 120
- model specifications 37–9
- motivation 36
- notation 37
- objective 36
- overview 35–6
- results 110–11, 118–19
- SAS Proc Mixed 41, 61–2
- hierarchical models versus marginal models 71–2
- high-density lipoprotein (HDL) 449
- HLM 74
 - overview 96
 - pedagogical exposition 96–103
 - statistical software 102–3
 - versus OLS 100–2
- HLM/2L 35–6, 39, 46–8
 - comparison of estimates 62–6
 - covariance components 52–5
 - estimation 39–45
 - fixed effects 53–5
 - hierarchical linear modelling 40–1, 61–2
 - hypothesis testing 39–45
 - inputting data 46–7
 - output 47–8
 - program specifications 47
 - random coefficients regression model 56
- homogeneity test 263
- homologous chromosomes 341
- homozygotes 329
- homozygous genotype 340
- human brain mapping 383–422
 - outline of tutorial 384
 - overview 383–8
 - see also* fMRI
- hyperparameters 260, 434
- hyperprior distribution 439
- hypothesis testing
 - covariance components 45
 - fixed effects 45
 - hierarchical linear modelling 44–5
 - HLM/2L 39–45
 - random effects 45
 - SAS Proc Mixed 39–45
 - type I and II errors 218–21
- identity-by-descent (IBD) 342–3, 346–9, 354
- identity link 8
- incomplete data 29–30
- independence, correlation structure 31
- independent variables 101
- informative for linkage 341
- informative prior information 89
- inner repeat factor (IRF) 188, 206
- Institute for Social Research 104
- intercept time 463
- International Registry of Vision Trials 254–5
- interpolation methods 429–30
- intra-class correlation 4
- intra-class correlation coefficient 31
- iterative generalized least squares (IGLS) 11, 73, 81, 108
- jack-knife method 374, 376
- K*-means clustering 365–8
- Kruskal–Wallis test 372
- L'Abbé plot 300
- larynx cancer case event realization 425
- Law of Likelihood 210–11, 214, 216, 219, 221, 233–4
- left hemisphere 386–7
- length of stay (LOS) 250
- leukaemia 363
- lidocaine 257, 261, 274
 - diagnostics 276
 - meta-analysis 273
 - prophylactic use 249–51
 - summary of results 276–7
 - use in heart attacks 275–7
 - fixed-effects results 275
 - homogeneity of study means 275
 - random-effects results 275–6
- likelihood-based linkage disequilibrium approaches 352
- likelihood based methods 210, 232
- likelihood functions 213–15, 224, 226, 228, 335
 - for relative risk 236
 - S-plus computer code 236–43
- likelihood methods for measuring statistical evidence 209–45
- likelihood ratio tests 138, 142
- likelihood ratios 209–12, 216, 218
 - Neyman–Pearson hypothesis testing theoryfill 219
- likelihood support interval 215
- likelihood theory 335
- likelihoods of models 333–5
- linear Bayes relative risk estimators 440
- linear mixed models 159
 - for repeated measures 163–5
 - MIXED procedure 167–73
- link functions 85
- linkage 340–1
 - complex diseases 348
 - disequilibrium mapping 350–2
 - equilibrium/disequilibrium 343–4
 - informative for 341

- linkage analysis
 - model-based 344–6, 350
 - model-free 346–50
- log-likelihood 77, 292
- log-likelihood ratio 335
- log-odds 304–5
 - versus latitude 313
- log-odds ratio 290, 295, 297–300, 308
- logit link 85
- longitudinal data
 - analysis 127–58
 - use of term 128
- longitudinal studies, examples 134
- Luria–Delbrck method for estimating
 - mutation rates in exponentially growing bacteria 351–2
- mapping
 - case events 427
 - see also* disease mapping; genetic mapping; human brain mapping
- marginal likelihood 434
- marginal models 9, 301
 - versus hierarchical models 71–2
- marginal residual analysis 441
- Markov chain Monte Carlo *see* MCMC
- maximum likelihood (ML) analysis of general
 - linear mixed model, statistical software for 143–4
- maximum likelihood (ML) estimates 43, 73, 188, 224, 297, 299, 301, 304, 335
 - under Normality 74
- MCMC
 - algorithms 88
 - methods 86, 88–91, 120, 321–2, 352, 436, 438
 - sampling 90
 - summary screen 91
- medical traits, familial distributions of 327
- Mendelian laws of inheritance 340
- Mendelian laws of segregation 328–9, 342
- Mendelian models 328
- meta-analysis 83–5, 249–87
 - advanced methods 289–324
 - analysis under homogeneity 291
 - Bayesian statistics in 321–2
 - beginning 252–4
 - bivariate 289, 299–307
 - defining the study outcome 257–9
 - definition 249
 - designs 252
 - diagnostics 265–8
 - evaluating retrieved literature 256–7
 - formulation 252–6
 - hierarchical linear modelling 120
 - inference 261–5
 - literature search 254–6
 - means and effect sizes 258–9
 - modelling variation 260–5
 - objectives 249
 - odds ratios 257–8
 - one-dimensional treatment effects 291–9
 - operational definitions 252
 - quantitative aspects of literature search 255
 - relative risks 257–8
 - reporting 273–5
 - risk differences 257–8
 - software 268–73
 - sources of information 254
 - study objectives 252
 - summary measures 257
 - summary statistics 257
 - test statistics 259
 - use to estimate average effect 250
 - with multiple outcomes 317–18
- meta-regression 307–14
- method of moments (MOM) 265, 276–7, 279
- Metropolis-Hastings (MH) algorithm 436
- Metropolis-Hastings (MH) sampling 88
- Metropolis-Hastings (MH) update 439
- microarrays 362–3
- Mini-Wright portable meter 7
- MINITAB 144
- misclassification rate 374–6
- misleading evidence 217–25
 - definition and implications 217–18
 - probability of observing 218, 221
- missing at random (MAR) 142, 192
- missing completely at random (MCAR) 192
- missing data, general linear mixed model 142–3
- mixed models 8, 71, 301, 333
 - BMDP code for 154–6
 - general linear 142–3
 - implementation 160
 - SAS code for 156–7
- MIXOR 74
- ML3, applications 144
- MLA code and output 122–3
- mLn 5, 321
- MLwin 74–5, 321
 - equation screen with estimates 76
 - equation screen with model display 75
 - equation screen with model unspecified 74
 - growth data example 75–80
 - output 124
 - predicted growth curves 77
- model-based standard error 17
- monogenic trait 345
- Monte Carlo 5 per cent monitoring bounds 225
- Morgan (unit) 341
- multi-dimensional scaling (MDS) 368–70
- multidisciplinary care for stroke inpatients 278–82
 - diagnostics 280–1
 - fixed-effects results 279

- homogeneity of study means 279
- random-effects results 279
- summary of results 281–2
- multilevel linear modelling 96
- multilevel mixed modelling 3–33
- multilevel modelling 5, 8, 10–11, 17–22
 - nature of 70–1
 - of medical data 69–93
 - with exchangeable correlation structure 21
- Multilevel Models Project 74
- multilocus models 348
- multi-parameter models 224
- multiple ascertainment of a family 336
- multiple logistic regression 244
- multiple logistic regression model 453–61
 - estimates of regression coefficients 454
- multiple membership structures 82–3
- multiple outcomes 317–18
- Multiple Risk Factor Intervention Trial (MRFIT) 104
- multivariable models
 - coronary heart disease 447–76
 - interpretation issues 474–5
 - parameters 461, 464
 - risk estimates 474–5
- multivariate data, use of term 129
- multivariate maximum likelihood (MML)
 - estimate 320
- multivariate normal mode, estimation 72–4
- multivariate response data 80–2

- naive pooled analysis, PEF 8, 13–14
- naive pooling 4
- naive regression model 9
- Nanostat 11
- National Center for Health Statistics (NCHS) 104
- National Cholesterol Education Program (NCEP)
 - Adult Treatment Panel III (ATP III) 449–53
- National Health and Nutrition Examination Survey I (NHANES-I) 106
- National Health and Nutrition Examination Survey III (NHANES-III) 103
- National Health Epidemiologic Follow-up (NHEFS) 106
- National Heart Lung and Blood Institute 448
- nested modelling 96
- nested repeated measures data 188
 - covariance models for 187–208
- neuroanatomy 386
- neurons 383
- Neurosurgery Clinical Trials Registry 254
- Neyman-Pearson hypothesis testing theory,
 - likelihood ratios 219
- NHLBI guidelines 103
- non-normal mixtures 317
- non-specific heterogeneity 433
- Normal standardized deviate 13

- Normality, maximum likelihood estimates
 - under 74
- normalized cross-covariance maps 409–10
- NTIS (National Technical Information Service)
 - bibliographic database 254
- nuclear families 328
- nuisance parameters 224–5, 228
- null hypothesis 345–7
- Nyquist (or folding) frequency 396

- obesity see overweight/obese adults
- observation level covariate 134
- oligonucleotides 362–3, 376
- optimization algorithm 143
- ordinary least squares (OLS) 38, 97, 117, 177
 - estimate 59
 - methods 96
 - modelling 129
 - procedure 99
 - versus HLM 100–2
- outcome measures 320
- outcomes, multiple 317–18
- outer repeat factor (ORF) 188, 206
- ovarian hormone values 196
- ovarian steroid secretion data 187–208
- ovarian steroid secretion study 206
- overweight/obese adults 95–126

- p*-values 201, 206, 296, 355, 370–2, 403, 441
- pairwise reasoning 217
- parametric modelling of affected sib pairs 347
- partial autocorrelation function (PACF) 90
- peak expiratory flow (PEF)
 - clinical characteristics 14
 - clinical conclusions 28–9
 - computing statistics of principal interest 22–4
 - correlation structure 8
 - correlation structure modelling 30–1
 - correlations arising from varying intercept 8–13, 15–21
 - data preparation 7
 - extending the correlation structure 21–9
 - varying intercept gradient 11
 - gold standard 6–7
 - interpreting the model 24–6
 - model criticism 26–7
 - naive pooled analysis 8, 13–14
 - notation 7–8
 - overview 5–6
 - results 13–29
 - statistical analysis 7–13
 - statistics of interest 6–7
- pedigree 330, 334, 352
 - analysis 328
 - founders 344–6

- penetrance 340
 - parameters 333
 - probabilities 332–3
- periodogram 398
- phenocopies 329
- phenotypes 328–9, 332–3, 340
- phenotypic data 331
- piecewise survival model 87
- pneumotachograph spirometer 6–7
- point event location 427
- point spread function 398
- points system 452–3, 474–5
 - algorithm for 461–3
- Poisson point process 431
- polygenic model 330, 335
- polygenic value 330
- polynomial trends over time 180–2
- population parameters 331
- PORT study
 - data analysis 49–59
 - description of physician and patient samples 50
 - distribution of patient satisfaction scores 51
 - intercept and slopes as outcomes model 52–5
 - HLM/2L 53
 - OLS estimates of intercepts and slopes 51
 - relationship between OLS intercepts and best linear unbiased predictions 59
 - relationship between OLS intercepts and slopes 52
 - results 49–62
- portable peak flow meters 5–29
- posterior distribution 260, 264
- posterior expected relative risk estimates 440
- precision in search process 255
- primary sampling units (PSUs) 37
- prior distribution 439
- priors 90
- profile likelihood 224–5
 - for a mean 234–5
- profile likelihood function 297–8
- publication bias 254, 267–8
- pulmonary function development in children 133
 - model selection and checking 149–54

- qualitative trait 346–8
- quantitative trait 348–50

- random coefficients 71, 100–1, 136
 - estimates of 57
 - modelling 112
 - regression 121
 - regression model 55, 96
 - HLM/2L 56
 - SAS Proc Mixed 57
- random effects 5, 8, 10–11, 136, 138, 141, 159, 432–5
 - analysis of covariance model (ANCOVA) with 56–9
 - estimating techniques 44
 - hypothesis tests 45
 - models 200, 208, 254, 260, 262–6, 296
 - multiple outcomes 320
 - random parameters 71
 - raw residual 12
 - raw total residual 12
 - recall in search process 255
 - recombination 340–1
 - recombination fraction 341, 345
 - red blood cells 329
 - referent risk factor profile 455, 462, 465–6
 - regression
 - for difference measure 307–8
 - Fourier transform in 396–7
 - on allocation 310
 - on latitude 308, 310
 - on year 310
 - regression analysis, of correlated data 127
 - regression coefficients 9, 71, 310
 - interpreting 29–30
 - regression inferences 10
 - regression parameters 136
 - relative risk 228–9
 - conditional likelihood for 235–9
 - estimation 428
 - likelihood function for 236
 - of disease 423
 - of disease to siblings and offspring 347
 - versus hazard rates 229
 - repeated measures
 - covariance structures for 165–7
 - linear mixed model for 163–5
 - repeated measures data 75
 - repeated measures data analysis 159–85
 - covariance structure 183
 - primary distinguishing features 183
 - residuals
 - analysis of 437–9
 - spatial distribution 442
 - summary functions of 437–9
 - respiratory cancer 441
 - counts 425
 - SMR thematic map 429
 - restricted maximum likelihood (REML) estimation 43–4, 73, 77–9, 137, 142, 161, 188, 264, 276–7, 279, 298
 - variance, covariance and correlation estimates 172
 - right hemisphere 386–7
 - risk estimates 452, 474–5
 - in coronary heart disease 447
 - multivariable models 474–5
 - points system 474–5

- risk factors
 - cardiovascular 230, 244
 - categories and reference values 454–5, 461–2, 465
 - in coronary heart disease 447–8
- RNA, overview 362
- robust standard error 13, 17, 21
- sampling bias 335
- sampling design and strategy, in genetic epidemiology 335–6
- sampling distribution, covariance matrix of 184
- SAS 5, 17, 74, 320, 376–8
 - code and output 123–4
 - code for mixed models 156–7
 - GENMOD 206
 - output for random-effects stroke meta-analysis 283
 - Proc GLM, comparison of estimates 62–6
 - Proc IML 318
 - Proc Mixed 27, 35–6, 39, 48–9, 143, 160, 163, 165, 167, 183, 188, 206–8, 268–72, 290, 292, 298, 301, 311, 314–15, 318–20
 - comparison of estimates 62–6
 - covariance components 53–5
 - estimation 39–45
 - fixed effects 53–5
 - hierarchical linear modelling specifications 41
 - hierarchical linear models 61–2
 - hypothesis testing 39–45
 - inputting data 48
 - intercept and slopes as outcomes model 54
 - output 48–9
 - program specifications 48
 - random coefficients regression model 57
 - Proc NLMIXED 184
 - prod mds 369
- schizophrenia clinical trial 130–3, 144–8
 - covariance matrix 147
 - design considerations 144–5
 - estimation and effect of missingness 146–8
 - model selection and testing 145–6
 - regression coefficients and standard errors for three covariance models 148
- schizophrenia clinical trial, case study 139
- Schwarz's Bayesian criterion (SBC) 174–5
- SCIL-Image 412
- secondary sampling units (SSUs) 37
- seemingly unrelated regression 96
- segregation analysis 340
- segregation variance 330
- sensitivity analysis 265–6, 277, 280
 - serum oestrogen levels 204
 - urine oestradiol levels 202
- serum oestrogen data 200–1
- serum oestrogen levels 192, 194
 - analysis results 205
 - sensitivity analysis 204
- serum oestrogen observations 198
- sex chromosomes 340
- shrinkage 59, 138
- shrinkage estimates 270–2
- shrinkage factors 12
- signal-to-noise ratio 400, 402
- simple linear regression model 9
 - extension 3–33
- simulation strategy 61–2
- Six Cities Study of Air Pollution and Health 133
- smoking effect on urinary oestradiol levels 201
- smoking status in CHD risk estimation 449
- software codes and their outputs 122–4
- SP model 206–8
- spatial covariance models 198–9
- specific heterogeneity 433
- S-plus 5, 9, 16, 74, 268, 320, 376–7, 412
 - code for fixed-effects lidocaine meta-analysis 282–3
 - code for fixed-effects stroke meta-analysis 283
 - code for likelihood functions 236–43
- S-plus function 228
- spotted cDNA array 363
- spotted cDNA arrays 376–7
- SPSS 320
- standard regression model 12
- standardized mean difference 259
- standardized mortality/morbidity ratios (SMRs) 439, 442
 - and standardization 427–9
- STATA 74, 320
- statistical evidence
 - likelihood methods for measuring 209–45
 - strength of 211–12
- statistical inference 13
- statistical software 46–9, 102–3, 320
 - for maximum likelihood analysis of general linear mixed model 143–4
 - see also* specific packages
- stroke
 - specialist care 252
 - see also* multidisciplinary care for stroke inpatients
- structural equation approach 306
- subject level covariate 134
- summary statistics 4–5, 250–1
- support intervals 215–16
- survival models 86–8
- syntenic chromosomes 340
- systolic blood pressure 449
- t*-distribution 296
- Tecumseh Mortality Follow-up Study (TMFS) 106
- tepee function 222–3

- time trends, modelling 135
- Toeplitz structure (TOEP) 167, 172, 178–9
- Tolbutamide 225–9, 231, 243–4
- transmission/disequilibrium tests (TDTs) 351, 355
- transmission probability 340
- treatment effect and baseline risk 306
- tubal ligation study 195
- tuberculosis, BCG vaccine against 293
- Tucson Epidemiological Study of Airways
Obstructive Disease 128
- type I and II errors of hypothesis testing 218–21
- Type II Diabetes Patient Outcomes Research
Team (PORT) study 35–6

- UN@AR(1) model 206, 208
- unbalanced repeated measures data analysis
127–58
- uncorrelated heterogeneity 433
- universal bound 221
- University Group Diabetes Program (UGDP)
209–45
 - analyses within subgroups 232–3
 - background 225–6
 - checking for imbalance 229–31
 - early termination of Tolbutamide arm 226–9
- UNIVRES (Directory of Federally Supported
Research in Universities) 254
- unstructured covariance 164

- unstructured structure 167, 172
- urinary oestradiol data 200
- urinary oestradiol levels 189–91, 193, 195
 - analysis results 203
 - sensitivity analysis 202
 - smoking effect on 201

- vaccination effect 300, 304–5, 312–13
- variance-covariance matrix 197
- varying regression intercept 8

- Wald test 13, 138
- weighted least squares (WLS) 43
 - regression 309
- Welsh–Allen (PneumoCheck) pneumotachograph
spirometer 6
- white matter 391
- WinBUGS 74
- Woolf’s formula 294

- X chromosome 328–9
- X-linked traits 328

- Y chromosome 328–9

- Z-Image 412
- zygote 328

Index compiled by Geoffrey C. Jones